| Literature DB >> 30675428 |
Vlado Perkovic1, Jonathan C Craig2,3, Worawon Chailimpamontree4, Caroline S Fox5, Guillermo Garcia-Garcia6, Mohammed Benghanem Gharbi7, Meg J Jardine8,9, Ikechi G Okpechi10,11, Neesh Pannu12, Benedicte Stengel13,14,15,16, Katherine R Tuttle17, Katrin Uhlig18,19, Andrew S Levey20.
Abstract
High-quality clinical trials are the cornerstone of evidence-based prevention and treatment of a disease, but nephrology has a strikingly weak base of such trials. Building the evidence base to improve outcomes for people with a kidney disease, therefore, requires both greater quantity and quality of clinical trials. To address these issues, we propose that we aim to enroll 30% of people with chronic kidney disease in trials by 2030. Goal 1: Strongly encourage and promote the conduct of clinical trials in people with chronic kidney disease to increase the number of clinical trials conducted. Goal 2: Optimize the design of clinical trials in people with chronic kidney disease. Goal 3: Increase the capacity for conducting clinical trials in people with chronic kidney disease.Entities:
Keywords: chronic kidney disease; clinical trial; clinical trial design; clinical trial endpoints
Year: 2017 PMID： 30675428 PMCID： PMC6341012 DOI： 10.1016/j.kisu.2017.07.009
Source DB: PubMed Journal: Kidney Int Suppl (2011) ISSN： 2157-1716